Virtual Library
Start Your Search
Yun Fan
Author of
-
+
P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.01-30 - Applicability of Lung-molGPA Index in Non-Small Cell Lung Cancer Patients with Different Gene Alterations and Brain Metastases (ID 12734)
16:45 - 18:00 | Presenting Author(s): Yun Fan
- Abstract
Background
The Lung-molGPA was based on the original Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) by incorporating recently reported gene alteration data for non-small cell lung cancer (NSCLC) patients with brain metastases (BM). However, the prognostic prediction value of DS-GPA and Lung-molGPA models remains undetermined, especially in patients with different molecule types.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 1184 NSCLC patients with BM analyses for clinical factors and outcomes were identified at Zhejiang Cancer Hospital, China. All prognostic factors were weighted for significance by hazard ratios. The applicability of DS-GPA and Lung-molGPA were reappraised in NSCLC patients with BM and various genetic profiles. Additionally, a modified Lung-molGPA, was newly developed for mutant NSCLC patients.
4c3880bb027f159e801041b1021e88e8 Result
The NSCLC patients in the present study had a median survival of 14.0 months from the time of BM diagnosis. Both DS-GPA and Lung-molGPA models could predict the outcomes (P<0.001), while Lung-molGPA model appeared to exhibit better accurate prediction. Furthermore, Lung-molGPA scores performed a discrimination capability in patients with gene variations (3.5-4.0 vs 2.5-3.0 vs 1.5-2.0 vs 0-1.0=62.0 vs 32.0 vs 17.7 vs 3.2 months, P<0.001). However, no significant difference was reached in wild-type patients (P=0.133). Regarding to the oncogene-positive NSCLC patients with BM, a modified Lung-molGPA index had been established derived from the prognostic factors with the C-index of 0.73 (95% CI: 0.73-0.80) to accurately calculate the survival probability (P<0.001).
8eea62084ca7e541d918e823422bd82e Conclusion
In an era of precision medicine, Lung-molGPA could precisely predict the prognosis of mutant NSCLC patients with BM, while not work in wild-type patients.
6f8b794f3246b0c1e1780bb4d4d5dc53